CHOP is a foundational multi-agent chemotherapy regimen used in the treatment of various non-Hodgkin and Hodgkin lymphomas. While it was once the standard of care as a standalone regimen, it is now most frequently administered in combination with the anti-CD20 monoclonal antibody rituximab (R-CHOP).
I. Regimen Components and Dosing (21-Day Cycle)
According to standard protocols for Diffuse Large B-cell Lymphoma (DLBCL), the components are administered as follows:
- C (Cyclophosphamide): 750 mg/m² IV on Day 1.
- H (Doxorubicin/Hydroxydaunorubicin): 50 mg/m² IV on Day 1.
- O (Vincristine/Oncovin): 1.4 mg/m² IV on Day 1, typically capped at 2 mg to minimize neurotoxicity.
- P (Prednisone): 100 mg PO daily on Days 1–5.
II. Clinical Indications and Place in Therapy
- Diffuse Large B-Cell Lymphoma (DLBCL): R-CHOP for 6 cycles is the standard of care for advanced disease. In localized, non-bulky disease with a favorable prognosis, 3–4 cycles may be used.
- Follicular Lymphoma (FL): It is a preferred first-line regimen when treatment is indicated. While Bendamustine + Rituximab (BR) often demonstrates superior progression-free survival, R-CHOP may be preferred in scenarios of aggressive biology, such as grade 3 disease or high PET uptake.
- Mantle Cell Lymphoma (MCL): Used as a less aggressive induction option for elderly patients or those with poor performance status.
- Peripheral T-cell Lymphoma (PTCL): Standard CHOP (without rituximab, as T-cells are CD20-negative) remains the backbone for PTCL-NOS and other subtypes.
- Burkitt Lymphoma (BL): The sources explicitly state that CHOP or R-CHOP is not adequate treatment for this very aggressive malignancy, which requires more intensive, dose-dense therapy.
- Hodgkin Lymphoma (HL): CHOP is not a first-line standard for classical HL (ABVD is preferred) but may be considered for patients >60 years old. For Nodular Lymphocyte Predominant HL (NLPHL), CHOP + rituximab is a common choice for bulky or advanced disease.
III. Role of Dose Intensity and Density
- Doxorubicin Intensity: Maintaining a doxorubicin dose intensity of >75% is associated with superior survival.
- Dose Density (CHOP-14 vs. CHOP-21): Historical trials showed an overall survival (OS) advantage for CHOP given every 14 days in elderly patients when rituximab was not used. However, when rituximab is added, R-CHOP-21 is equivalent to R-CHOP-14 in OS, leading to R-CHOP-21 remaining the standard.
- R-mini-CHOP: A attenuated-dose version of the regimen (reduced doses of C, H, and O) is recommended for patients >80 years of age with significant comorbidities.
IV. Oncology Pharmacist Considerations
- Cardiotoxicity: Doxorubicin carries a lifetime cumulative dose limit. It can be administered as a continuous IV infusion (CIVI) to potentially decrease the risk of cardiotoxicity.
- Extravasation: Both doxorubicin (vesicant) and vincristine (vesicant/irritant) require careful administration through a central line or a high-quality peripheral site.
- Supportive Care:
- G-CSF: Routine prophylactic growth factor support is generally not required for R-CHOP-21 unless the patient is >65 years old or has other specific risk factors.
- Rituximab Infusions: Pharmacists must monitor for infusion-related reactions, particularly during the first dose. A “rapid” 90-minute infusion protocol may be used starting with Cycle 2 if the first dose was well-tolerated.
- Viral Screening: Screening for Hepatitis B is mandatory before starting rituximab due to the risk of reactivation.